POEMS Syndrome Clinical Trials

• Newly diagnosed POEMS syndrome meeting the Dispenzieri diagnostic criteria (2023 version);

• Age 18-75 years;

• ECOG performance status 0-3, with an estimated life expectancy \>3 months;

• No active infective diseases;

• No prior anti-POEMS therapy except for corticosteroids;

• No severe organic impairment of major organs, meeting the following laboratory requirements: creatinine clearance ≥40 mL/min, total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤2.5 × ULN; cardiac enzymes \<2 × ULN; left ventricular ejection fraction within normal range on echocardiography, and no clinically significant electrocardiogram abnormalities;

• Absolute neutrophil count ≥1.5 × 10\^9/L without prior growth factor support; platelet count ≥50 × 10\^9/L without platelet transfusion within 7 days prior to screening; hemoglobin ≥60 g/L;

• Ability to swallow and take medication orally;

• Completion of all screening and assessments as outlined in the study protocol;

⁃ Signed informed consent for chemotherapy.